GleamWall
中文EN

SNY Sanofi IFRS Annual reports only

Pharmaceutical Preparations · Nasdaq · SEC CIK 1121404 · Reporting currency EUR · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY6.2%
TTM net income YoY40.5%
TTM EPS YoY43.8%
Revenue 3-yr CAGR5.0%
Net income 3-yr CAGR-2.3%

Margins

Gross margin77.2%
Operating margin14.5%
Net margin17.9%
FCF margin—
EBITDA margin—

Returns

ROE10.5%
ROA6.0%
ROIC (approx.)6.0%
Asset turnover0.34x

Leverage & solvency

Liabilities / assets43.4%
Debt / equity0.26x
Current ratio1.09x
Interest coverage11.27x

Cash quality & payout

Operating cash flow / net income1.38x
Accruals ratio-2.3%
Payout ratio61.1%
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Unit: EUR FY20252025-12-31FY20242024-12-31
Income statement
Revenue43.63B41.08B
Cost of revenue13.05B13.21B
Gross profit33.67B31.08B
R&D expense7.84B7.39B
SG&A expense9.54B9.18B
Operating income6.34B7.25B
Interest expense563.00M1.07B
Income tax1.04B1.20B
Net income7.81B5.56B
EPS (basic)6.404.44
EPS (diluted)6.374.43
Weighted avg. shares (diluted)1.23B1.26B
Balance sheet
Cash & equivalents7.66B7.44B
Receivables8.41B7.68B
Inventory10.21B9.43B
Current assets30.95B42.59B
PP&E, netmay include right-of-use assets (IFRS)10.05B10.09B
Goodwill41.30B43.38B
Intangibles26.26B22.63B
Total assets126.81B132.80B
Current liabilities28.34B29.16B
Short-term debt4.34B4.21B
Long-term debt14.25B11.79B
Total debt18.59B16.00B
Total liabilities55.09B54.94B
Shareholders' equity71.38B77.51B
Net debt10.93B8.56B
Cash flow statement
Operating cash flow10.75B9.08B
Investing cash flow-2.45B-4.41B
Financing cash flow-8.21B-5.76B
Stock-based compensation313.00M278.00M
Dividends paid4.77B4.70B
Share buybacks5.03B302.00M

Free plan shows the latest 2 periods; Pro shows all 11 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.